https://bay2666605inhibitor.co....m/remodeling-involvi
Link between 2199 patients enrolled, 1095 were randomized to edoxaban and 1104 to enoxaparin-warfarin. Patients obtaining concomitant APT had been older; more naïve to supplement K antagonist; had lower creatinine approval; and more prone to have reputation for coronary artery disease, hypertension, diabetes, or ischemic stroke/transient ischemic attack. In patients getting vs maybe not receiving concomitant APT, primary efficacy event rate was numerically higher (0.92% vs 0.60%, p = 0.64) and pri
Like
Comment
Share
